We are live on ! Find out more
D.E. Shaw & Co

D.E. Shaw & Co Portfolio holdings

AUM $166B
1-Year Est. Return 43.98%
 

D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.

This Fund
S&P 500
This Quarter Est. Return
+0.31%
1 Year Est. Return
+43.98%
3 Year Est. Return
+138.44%
5 Year Est. Return
+164.23%
10 Year Est. Return
+713.02%
AUM
$81.2B
AUM Growth
+$1.02B
Cap. Flow
+$958M
Cap. Flow %
1.18%
Top 10 Hldgs %
10.24%
Holding
4,189
New
550
Increased
1,503
Reduced
1,391
Closed
422

Sector Composition

Rank Sector Weight
1 Technology 14.59%
2 Consumer Discretionary 12.73%
3 Healthcare 11.62%
4 Financials 8.02%
5 Industrials 6.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NXE icon
3676
NexGen Energy
NXE
$6.05B
$50K ﹤0.01%
38,300
-177,800
-82% -$245K
GNC
3677
DELISTED
GNC Holdings, Inc.
GNC
$50K ﹤0.01%
23,349
-468,932
-95% -$938K
LXRX icon
3678
Lexicon Pharmaceuticals
LXRX
$1.02B
$48K ﹤0.01%
15,862
-49,575
-76% -$153K
GALT icon
3679
Galectin Therapeutics
GALT
$229M
$47K ﹤0.01%
12,927
-6,571
-34% -$23.8K
PDSB icon
3680
PDS Biotechnology
PDSB
$38.1M
$46K ﹤0.01%
13,678
VTVT icon
3681
vTv Therapeutics
VTVT
$121M
$46K ﹤0.01%
740
-1,148
-61% -$64.8K
CLUB
3682
DELISTED
Town Sports International Holdings, Inc.
CLUB
$46K ﹤0.01%
28,051
-19,843
-41% -$35K
TKKSW
3683
DELISTED
TKK Symphony Acquisition Corporation Warrant
TKKSW
$46K ﹤0.01%
574,288
-25,500
-4% -$2.34K
CYH icon
3684
Community Health Systems
CYH
$385M
$43K ﹤0.01%
+12,079
New +$31.5K
ECOR icon
3685
electroCore
ECOR
$51.4M
$43K ﹤0.01%
+1,304
New +$41.2K
ADAP
3686
DELISTED
Adaptimmune Therapeutics
ADAP
$40K ﹤0.01%
26,579
-51,411
-66% -$120K
NBRV
3687
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$40K ﹤0.01%
+79
New +$44.6K
SREV
3688
DELISTED
ServiceSource International, Inc.
SREV
$39K ﹤0.01%
44,600
+1,200
+3% +$1.09K
HL icon
3689
Hecla Mining
HL
$10.2B
$38K ﹤0.01%
+21,544
New +$38.8K
NE
3690
DELISTED
Noble Corporation
NE
$38K ﹤0.01%
29,683
-52,298
-64% -$89.3K
NGD
3691
DELISTED
New Gold Inc
NGD
$37K ﹤0.01%
36,692
+6,545
+22% +$7.96K
CLDX icon
3692
Celldex Therapeutics
CLDX
$2.77B
$36K ﹤0.01%
16,719
-2,900
-15% -$6.71K
TEN
3693
Tsakos Energy Navigation Ltd
TEN
$1.19B
$36K ﹤0.01%
2,437
-1,749
-42% -$26.9K
AUO
3694
DELISTED
AU Optronics Corp
AUO
$33K ﹤0.01%
13,215
-157,938
-92% -$414K
VBIV
3695
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$31K ﹤0.01%
+2,165
New +$45.3K
GNCA
3696
DELISTED
Genocea Biosciences, Inc.
GNCA
$31K ﹤0.01%
10,747
-10,653
-50% -$36.4K
CVIA
3697
DELISTED
Covia Holdings Corporation Common Stock
CVIA
$30K ﹤0.01%
+14,735
New +$27.4K
SSI
3698
DELISTED
Stage Stores Inc
SSI
$30K ﹤0.01%
15,706
-3,400
-18% -$2.93K
DSKE
3699
DELISTED
Daseke, Inc. Common Stock
DSKE
$29K ﹤0.01%
+11,408
New +$32.1K
VTLE
3700
DELISTED
Vital Energy
VTLE
$28K ﹤0.01%
+580
New +$32.1K

Similar funds

D.E. Shaw & Co's Q3 2019 Portfolio in Review

As of Q3 2019, D.E. Shaw & Co held 4,189 positions worth $81.2B, up 1.3% from $80.2B the previous quarter. Its ten largest holdings account for 10% of the portfolio.

D.E. Shaw & Co's Q3 2019 filing shows 550 new, 1,503 increased, 1,391 reduced and 422 closed positions. Its largest new stake was iShares iBoxx $ High Yield Corporate Bond ETF: 3,554,658 shares worth $310M. The largest sale was Anadarko Petroleum, an estimated $567M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 16% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • D.E. Shaw & Co's largest Q3 2019 buy was iShares iBoxx $ High Yield Corporate Bond ETF: 3,554,658 shares worth $310M.
  • D.E. Shaw & Co added most to PayPal in Q3 2019, an estimated $354M increase.
  • D.E. Shaw & Co's biggest Q3 2019 reduction was Fidelity National Information Services, cutting an estimated $410M.
  • D.E. Shaw & Co fully exited Anadarko Petroleum in Q3 2019, selling an estimated $567M.
  • D.E. Shaw & Co's ten largest holdings make up 10% of its $81.2B portfolio in Q3 2019.
  • D.E. Shaw & Co opened 550 new positions and closed 422 in Q3 2019.
  • D.E. Shaw & Co's portfolio value rose 1.3% quarter-over-quarter to $81.2B.

Based on D.E. Shaw & Co's 13F filing for Q3 2019, filed 14 Nov 2019.